TrialAntimicrobial agents and chemotherapy2022

Delamanid Added to an Optimized Background Regimen in Children with Multidrug-Resistant Tuberculosis: Results of a Phase I/II Clinical Trial.

Anthony J Garcia-Prats et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.